269 related articles for article (PubMed ID: 23165153)
1. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
3. Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells.
Matsunaga T; Yamaguchi A; Morikawa Y; Kezuka C; Takazawa H; Endo S; El-Kabbani O; Tajima K; Ikari A; Hara A
Anticancer Drugs; 2014 Sep; 25(8):868-77. PubMed ID: 24743520
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
Matsunaga T; Yamaji Y; Tomokuni T; Morita H; Morikawa Y; Suzuki A; Yonezawa A; Endo S; Ikari A; Iguchi K; El-Kabbani O; Tajima K; Hara A
Free Radic Res; 2014 Nov; 48(11):1371-85. PubMed ID: 25156503
[TBL] [Abstract][Full Text] [Related]
5. Development of cisplatin resistance in breast cancer MCF7 cells by up-regulating aldo-keto reductase 1C3 expression, glutathione synthesis and proteasomal proteolysis.
Kobayashi M; Yonezawa A; Takasawa H; Nagao Y; Iguchi K; Endo S; Ikari A; Matsunaga T
J Biochem; 2022 Jan; 171(1):97-108. PubMed ID: 34676395
[TBL] [Abstract][Full Text] [Related]
6. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Beranič N; Gobec S; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
[TBL] [Abstract][Full Text] [Related]
7. Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Shiiba M; Yamagami H; Yamamoto A; Minakawa Y; Okamoto A; Kasamatsu A; Sakamoto Y; Uzawa K; Takiguchi Y; Tanzawa H
Oncol Rep; 2017 Apr; 37(4):2025-2032. PubMed ID: 28259989
[TBL] [Abstract][Full Text] [Related]
8. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
Hevir N; Vouk K; Sinkovec J; Ribič-Pucelj M; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):217-26. PubMed ID: 21232532
[TBL] [Abstract][Full Text] [Related]
9. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
10. Availability of aldo-keto reductase 1C3 and ATP-binding cassette B1 as therapeutic targets for alleviating paclitaxel resistance in breast cancer MCF7 cells.
Matsunaga T; Horinouchi M; Saito H; Hisamatsu A; Iguchi K; Yoshino Y; Endo S; Ikari A
J Biochem; 2023 Mar; 173(3):167-175. PubMed ID: 36413758
[TBL] [Abstract][Full Text] [Related]
11. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
[TBL] [Abstract][Full Text] [Related]
12. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
[TBL] [Abstract][Full Text] [Related]
13. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
15. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
16. Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival.
Marín YE; Seiberg M; Lin CB
Exp Dermatol; 2009 Jul; 18(7):611-8. PubMed ID: 19320734
[TBL] [Abstract][Full Text] [Related]
17. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
19. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
20. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization.
Heibein AD; Guo B; Sprowl JA; Maclean DA; Parissenti AM
BMC Cancer; 2012 Aug; 12():381. PubMed ID: 22938713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]